ARMP
AMEX · Biotechnology
Armata Pharmaceuticals Inc
$5.89
+0.01 (+0.17%)
Financial Highlights (FY 2026)
Revenue
4.51M
Net Income
-160,031,078
Gross Margin
—
Profit Margin
-3,544.0%
Rev Growth
-3.8%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 64.0% | 64.0% |
| Operating Margin | -747.0% | -672.3% | -25.7% | -26.9% |
| Profit Margin | -3,544.0% | -3,366.8% | -31.4% | -24.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 4.51M | 4.69M | 51.72M | 48.38M |
| Gross Profit | — | — | 33.09M | 30.96M |
| Operating Income | -33,725,950 | -31,555,624 | -13,268,820 | -13,017,580 |
| Net Income | -160,031,078 | -149,732,789 | -16,237,176 | -12,069,043 |
| Gross Margin | — | — | 64.0% | 64.0% |
| Operating Margin | -747.0% | -672.3% | -25.7% | -26.9% |
| Profit Margin | -3,544.0% | -3,366.8% | -31.4% | -24.9% |
| Rev Growth | -3.8% | -3.8% | -2.8% | -3.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 107.00M | 137.33M |
| Total Equity | — | — | 94.95M | 97.16M |
| D/E Ratio | — | — | 1.13 | 1.41 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -32,320,545 | -31,920,696 | -19,844,642 | -21,697,061 |
| Free Cash Flow | — | — | -12,228,215 | -11,985,347 |